3SBio Bundle
What's the Story Behind 3SBio's Rise in Biotech?
From a modest beginning in 1993 to a landmark deal with Pfizer, 3SBio's journey is a compelling narrative of innovation and growth within the 3SBio SWOT Analysis. This Chinese biotech firm has rapidly ascended the ranks of the pharmaceutical industry, making significant strides in oncology, nephrology, and immunology. Discover how this biopharmaceutical company carved its niche in the global healthcare market.
This exploration into the 3SBio company's brief history will delve into its key milestones, financial performance, and strategic partnerships, providing a comprehensive overview of its evolution. We'll examine the 3SBio product portfolio overview, its impact on Chinese healthcare, and its future prospects, offering valuable insights for investors and industry observers alike. Uncover the factors that have shaped the 3SBio history and its position today.
What is the 3SBio Founding Story?
The 3SBio company, a prominent player in the biopharmaceutical industry, traces its origins back to 1993. Founded by Dr. Jing Lou and Dan Lou, the company set out to make a mark in the burgeoning field of biotechnology, specifically within China.
With its headquarters established in Shenyang, Liaoning, China, 3SBio embarked on a journey to become a leading biopharmaceutical company. Their primary goal was to improve patient outcomes by developing innovative, high-quality biopharmaceutical products. This commitment positioned 3SBio as a pioneer in the Chinese biotechnology sector.
The founding of 3SBio was influenced by the increasing demand for advanced therapies within China. The company focused on the research, development, manufacturing, and marketing of biopharmaceutical products, with an early emphasis on recombinant protein products. While specific details about initial funding sources are not readily available, the company's sustained growth suggests early strategic investments. The expertise of the founding team in biopharmaceuticals laid the groundwork for the company's future success in developing innovative drugs.
3SBio's Founding and Early Years
3SBio's history began in 1993 with a vision to lead in biotechnology. The company aimed to address unmet medical needs in areas like oncology, nephrology, and immunology.
- Founded in 1993 by Dr. Jing Lou and Dan Lou.
- Headquartered in Shenyang, Liaoning, China.
- Focused on research, development, manufacturing, and marketing of biopharmaceutical products.
- Early emphasis on recombinant protein products.
3SBio SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of 3SBio?
The early phase of the 3SBio company focused on establishing a strong foothold in biopharmaceutical research, development, and manufacturing. Key products like TPIAO, EPIAO, and SEPO became prominent in their respective fields. This early focus set the stage for 3SBio's growth as a leading player in the pharmaceutical industry.
Key Product Success
TPIAO, the world's only commercial recombinant human thrombopoietin (rhTPO), played a crucial role in 3SBio's early success. In 2024, TPIAO recorded sales of RMB 5.062 billion, marking a 20.4% year-on-year increase. This growth expanded its market share to 34.3%, making it the leading drug in China's thrombocytopenia treatment market.
Product Portfolio Expansion
3SBio expanded its product portfolio to include Cipterbin, an anti-HER2 monoclonal antibody, and Mandi, a hair loss treatment. These launches contributed to steady sales growth. The company's strategic approach to product diversification helped solidify its position in the Competitors Landscape of 3SBio.
Strategic Partnerships and Acquisitions
Strategic partnerships were key to 3SBio's expansion and diversification. In October 2024, 3SBio partnered with Haihe Biopharma to acquire commercialization rights for paclitaxel oral solution, Liporaxel. The company also secured rights for Clifutinib and HER2-targeting ADC DB-1303, broadening its oncology offerings.
Financial Performance and Global Expansion
In 2024, 3SBio achieved strong revenue growth. Total revenue reached approximately RMB 9.108 billion, a 16.5% year-on-year increase. Gross profit increased by 17.9% year-on-year to approximately RMB 7.828 billion, and net profit attributable to owners of the parent rose by 34.9% year-on-year to approximately RMB 2.09 billion. In 2023, 3SBio collaborated with 5 international biopharma companies, enhancing its distribution capabilities across 30 countries.
3SBio PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in 3SBio history?
The 3SBio company has achieved several significant milestones throughout its history, solidifying its position in the biopharmaceutical industry. The 3SBio history reflects its growth and impact on the Chinese biotech sector.
| Year | Milestone |
|---|---|
| 2024 | Approval for commercial launch of three drugs, including eltrombopag for oral suspension. |
| 2024 | Submission of new drug applications for four products, such as long-acting erythropoietin (SSS06) and anti-IL-7 monoclonal antibody (608). |
| 2024 | TPIAO, the company's flagship product, received approval for the treatment of primary immune thrombocytopenia in children and adolescents and was renewed in the 2024 National Reimbursement Drug List (NRDL). |
| 2025 | Pfizer entered into an exclusive global licensing agreement with 3SBio for SSGJ-707. |
3SBio's commitment to innovation is evident in its robust pipeline and strategic partnerships. The company's research and development history showcases a focus on creating groundbreaking treatments.
TPIAO Innovation
TPIAO continues to be a groundbreaking innovation as the world's only commercial recombinant human thrombopoietin (rhTPO). In 2024, TPIAO sales reached RMB 5.062 billion.
Pipeline Development
3SBio's pipeline currently includes 30 product candidates, with 10 candidates advanced to clinical phase III. The company's product portfolio overview highlights its diverse range of therapies.
707 Clinical Trials
707, a bispecific antibody targeting PD-1/VEGF, is undergoing four clinical trials for various cancers. The phase III clinical trial for first-line treatment of PD-L1-positive advanced non-small cell lung cancer was approved.
Autoimmune Disease Pipeline
The autoimmune disease pipeline shows significant progress, with the phase III clinical trial of anti-IL-17A mAb (608) for plaque psoriasis meeting all efficacy endpoints. Its new drug application was submitted.
Pfizer Partnership
In May 2025, Pfizer entered into an exclusive global licensing agreement with 3SBio for SSGJ-707. This deal included an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion, along with a $100 million equity investment from Pfizer.
Strategic Alliances
The strategic partnerships, such as the one with Pfizer, demonstrate 3SBio's ability to secure major deals in the pharmaceutical industry. This highlights the company's strategic foresight and innovation capabilities.
Despite its successes, 3SBio, like any biopharmaceutical company, faces challenges. The Owners & Shareholders of 3SBio navigate a complex landscape.
Market Competition
The pharmaceutical industry is highly competitive, requiring continuous innovation and strategic partnerships. 3SBio must stay ahead of competitors to maintain its market position.
Regulatory Hurdles
Navigating regulatory approvals for new drugs can be a lengthy and complex process. 3SBio must comply with stringent regulations to bring its products to market.
R&D Investment
Significant investment in research and development is essential for maintaining a strong pipeline. 3SBio needs to allocate resources effectively to drive innovation.
Commercialization Challenges
Successfully commercializing new drugs requires effective marketing and distribution strategies. 3SBio must build strong commercial capabilities to maximize product sales.
Global Expansion
Expanding into global markets presents both opportunities and challenges. 3SBio needs to adapt to different market dynamics and regulatory environments.
Financial Performance
Maintaining strong financial performance is crucial for sustaining growth and investment in R&D. 3SBio must manage its finances effectively to ensure long-term success.
3SBio Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for 3SBio?
The 3SBio company has a rich history, marked by strategic growth and innovation. The company's journey began in 1993 in Shenyang, China. It has since evolved into a prominent player in the biopharmaceutical industry. The 3SBio history includes several key milestones, from being the first Chinese biopharmaceutical company to list on Nasdaq to its relisting on the Hong Kong Stock Exchange. 3SBio's commitment to innovation and strategic collaborations has positioned it for sustained growth in the pharmaceutical industry.
| Year | Key Event |
|---|---|
| 1993 | 3SBio Inc. is founded in Shenyang, China. |
| 2007 | 3SBio becomes the first Chinese biopharmaceutical company to list on Nasdaq. |
| 2015 | The company privatizes from Nasdaq and relists on the Hong Kong Stock Exchange (01530.HK). |
| 2023 | 3SBio celebrates its 30th anniversary, investing over RMB 1 billion in R&D. |
| October 2024 | 3SBio partners with Haihe Biopharma for commercialization rights to paclitaxel oral solution, Liporaxel. |
| 2024 (Annual Results) | Revenue grows 16.5% year-on-year to RMB 9.108 billion, with net profit up 34.9% year-on-year to RMB 2.09 billion. |
| 2024 | Three new drugs receive commercial launch approval, and new drug applications are submitted for four products. |
| May 2025 | Pfizer signs an exclusive global licensing agreement with 3SBio for its oncology drug candidate SSGJ-707, with an upfront payment of $1.25 billion. |
| 2025 (Expected) | 3SBio plans to initiate the first Phase III study for SSGJ-707 in China. |
Strategic Partnerships
3SBio's partnerships, like the recent agreement with Pfizer, are pivotal for its future. These collaborations facilitate the commercialization of innovative drugs and expand its global reach. The Pfizer deal, including a $1.25 billion upfront payment, underscores 3SBio's potential in the pharmaceutical industry. These strategic alliances are key for sustainable growth.
Expanding Pipeline
3SBio's robust pipeline of 30 product candidates, with 10 in Phase III, indicates a strong future. The company's focus on R&D and new drug applications, such as those for long-acting erythropoietin and anti-IL-7 monoclonal antibody, highlights its commitment to innovation. This expanding pipeline is crucial for maintaining a competitive edge.
Financial Performance
The financial performance of 3SBio in 2024 shows impressive growth. Revenue increased by 16.5% to RMB 9.108 billion, and net profit surged by 34.9% to RMB 2.09 billion. Sales of TPIAO, a flagship product, reached RMB 5.062 billion, a 20.4% increase. The company's strong financial position supports its future investments.
Future Outlook
Looking ahead, 3SBio is poised for continued growth and innovation. The company plans to expand its therapeutic coverage and maintain market leadership through ongoing innovation and strategic collaborations. Analysts predict sustained growth, with some revising up earnings forecasts. To learn more about the Revenue Streams & Business Model of 3SBio, explore further details.
3SBio Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Competitive Landscape of 3SBio Company?
- What is Growth Strategy and Future Prospects of 3SBio Company?
- How Does 3SBio Company Work?
- What is Sales and Marketing Strategy of 3SBio Company?
- What is Brief History of 3SBio Company?
- Who Owns 3SBio Company?
- What is Customer Demographics and Target Market of 3SBio Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.